GE Announces Haliade-X, the World’s Most Powerful Offshore Wind Turbine
1.3.2018 14:15:00 EET | Business Wire | Press release
GE Renewable Energy (NYSE:GE) today unveiled its plan to develop the largest, most powerful offshore wind turbine: the Haliade-X. Featuring a 12 MW direct drive generator and an industry leading gross capacity factor of 63 percent, the Haliade-X will produce 45 percent more energy than any other offshore turbine available today 2 . GE will invest more than $400 million over the next three to five years in development and deployment of the Haliade-X.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180301005661/en/
Featuring a 12 MW direct drive generator and an industry leading gross capacity factor of 63 percent, the Haliade-X will produce 45 percent more energy than any other offshore turbine available today. (Photo: Business Wire)
John Flannery, Chairman and CEO of GE said, “We want to lead in the technologies that are driving the global energy transition. Offshore wind is one of those technologies and we will bring the full resources of GE to make the Haliade-X program successful for our customers.”
Towering 260 meters over the sea, more than five times the size of the iconic Arc de Triomphe in Paris, France, the Haliade-X 12 MW carries a 220-meter rotor. Designed and manufactured by LM Wind Power, the 107-meter-long blades will be the longest offshore blades to date and will be longer than the size of a soccer field. One Haliade-X 12 MW turbine will generate up to 67 GWh annually 2 , enough clean power for up to 5,000 households per turbine, and up to 300,000 U.S. households in a 750 MW windfarm configuration.
Jérôme Pécresse, President and CEO of GE Renewable Energy said, “The renewables industry took more than 20 years to install the first 17 GW of offshore wind. Today, the industry forecasts that it will install more than 90 GW over the next 12 years. This is being driven by lower cost of electricity from scale and technology. The Haliade-X shows GE’s commitment to the offshore wind segment and will set a new benchmark for cost of electricity, thus driving more offshore growth.”
The ability to produce more power from a single turbine means a smaller number of turbines in the total farm, which translates to less capital expenditure for the balance of plant and reduced risk in project execution as the installation cycle time is reduced. It also simplifies operation and maintenance of the wind farm. All of this reduces the investment and operation cost for developers, makes offshore wind projects more profitable, and ultimately lowers cost of electricity for consumers.
John Lavelle, CEO of Offshore Wind at GE Renewable Energy said “The Haliade-X 12 MW will help our customers in an increasingly competitive offshore environment, and through its size and digital functionality provide important value across manufacturing, installation and operation.”
GE’s Haliade-X platform is designed to offer greater efficiency in generating power from the wind that is available. With a 63 percent gross capacity factor1, the Haliade-X 12 MW is five to seven points above the current industry benchmark. Therefore, it will produce more energy per MW installed, which will significantly increase returns for customers.
To design and build the Haliade-X platform, GE Renewable Energy is relying on an unprecedented collaboration across the GE portfolio, leveraging the knowledge of GE’s Onshore wind team, with 50,000 turbines in the field; the blade expertise of LM Power Wind; the GE Power and GE Aviation engineers for peer reviews of component and systems design; the Global Research Center for control systems and component validation; and GE Digital for supporting digital modelling, analytics and app development, the program is a GE-wide effort.
GE Renewable Energy aims to supply its first nacelle for demonstration in 2019 and ship the first units in 2021.
1 “Capacity factor” compares how much energy was generated against the maximum that could have been produced at continuous full power operation during a specific period of time.
2 Based on wind conditions on a typical German North Sea site.
About GE Renewable Energy
GE Renewable Energy is a $10 billion start-up that brings together one of the broadest product and service portfolios of the renewable energy industry. Combining onshore and offshore wind, hydro and innovative technologies such as concentrated solar power and more recently turbine blades, GE Renewable Energy has installed more than 400+ gigawatt capacity globally to make the world work better and cleaner. With more than 22,000 employees present in more than 55 countries, GE Renewable Energy is backed by the resources of the world's first digital industrial company. Our goal is to demonstrate to the rest of the world that nobody should ever have to choose between affordable, reliable, and sustainable energy. Follow us @GErenewables and www.gerenewableenergy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180301005661/en/
Contact information
GE Renewable Energy
Sebastien Duchamp
Sebastien.duchamp@ge.com
Phone:
+33673195964
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
